Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer
sites of metastases. The trial involves surgery (removal of the prostate), six months of
hormone therapy, and stereotactic body radiotherapy to the sites of metastasis.